Clinical trial · Interventional
Parenteral Nutrition Support for Patients With Pancreatic Cancer
Parenteral Nutrition Support for Patients With Pancreatic Cancer. A Phase II Study.
NCT00919659CI-TRIAL-00002375completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the additional nutrition support is improving the nutritional status of patients suffering cancer caxechia or not.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer Cachexia | — | UNRESOLVED | — |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| parenteral nutrition | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- parenteral nutrition
- description
- 25kcal/kg/bw /day via parenteral support
- interventionNames
- Dietary Supplement: parenteral nutrition
Primary outcomes (1)
- measure
- nutritional status presented by phase angle
- timeFrame
- 12 weeks
Secondary outcomes (1)
- measure
- quantity of port infections, quantity of oedema, quantity of diarrhea
- timeFrame
- 12 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * histological proved pancreatic cancer * progressive cancer cachexia * refractive to enteral supplementation * informed consent Exclusion Criteria: * prefinal status * septic disease
References
Publications (1)
- DERIVEDPelzer U, Arnold D, Govercin M, Stieler J, Doerken B, Riess H, Oettle H. Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer. 2010 Mar 9;10:86. doi: 10.1186/1471-2407-10-86. PMID 20214798